Page 14 - 2022_01-Haematologica-web

S.M. Smith and G. Salles
ited guidance on surveillance strategies that balance risks and benefits of repeated radiological imaging, and, of course, cure remaining elusive. A clear modern-day obsta- cle is the ongoing COVID-19 pandemic which must be considered within the decision-making process. The neg- ative impact of anti-lymphoma therapy on immunity puts our patients at higher risk of morbidity and mortali- ty. There are now emerging data that rituximab or anti- CD20 antibody therapy interferes with a robust antibody response to the vaccine for approximately 12 months,8 and the use of agents such as bendamustine suppresses
both B- and T-cell function. The discussion on risks versus benefits of treatment and treatment selection has never been so crucial. This first series on indolent lymphomas artfully presents the progress to date in detail, with dis- cussion of the many challenges that remain.
Disclosures
No conflicts of interest to disclose.
Contributions
The authors contributed equally.
References
1.Sarkozy C, Maurer MJ, Link BK, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019;37(2):144-152.
2. Cartron G, Trotman J. Time for an individ- ualized approach to first-line management of follicular lymphoma. Haematologica. 2022;107(1):7-18.
3.Qualls D, Salles G. Prospects in the man- agement of patients with follicular lym- phoma beyond first-line therapy. Haematologica. 2022;107(1):19-34.
4. Cheah CY, Zucca E, Rossi D, Habermann TM. Marginal zone lymphoma: present status and future perspectives. Haematologica. 2022;107(1):35-43
5. Schuster SJ, Dickinson MJ, Dreyling M, et al. Efficacy and safety of tisagenlecleucel (Tisa-Cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): primary analysis of the phase 2 Elara trial. J Clin Oncol. 2021;39(15_ Suppl):7508.
6. Jacobson CA, Chavez JC, Sehgal AR, et al. Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). Blood. 2020;136(Suppl_1):40-41.
7. Roulland S, Faroudi M, Mamessier E, Sungalee S, Salles G, Nadel B. Early steps of follicular lymphoma pathogenesis. Adv Immunol. 2011;111:1-46.
8. Pasqualucci L. Molecular pathogenesis of germinal center-derived B cell lymphomas.
Immunol Rev. 2019;288(1):240-261.
9. Kumar E, Pickard L, Okosun J. Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation. Br
J Haematol. 2021;194(5):810-821.
10. Vela V, Juskevicius D, Dirnhofer S, Menter T, Tzankov A. Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnos- tic potential for assignment of organ origin. Virchows Arch. 2021;Sep 8. [Epub ahead of
print].
11.Gurion R, Rozovski U, Itchaki G, et al.
Humoral serologic response to the BNT162b2 vaccine is abrogated in lym- phoma patients within the first 12 months following treatment with anti-CD2O anti- bodies. Haematologica. 2021;Jul 29. [Epub ahead of print].
6
haematologica | 2022; 107(1)